The main pharmaceutical ingredients of Enactuzumab

Elranatamab (Elranatamab) is a genetically engineered, recombinant, fully human IgG2 subtype bispecific monoclonal antibody. The core of its design is to simultaneously recognize and bind two different types of targeting molecules: the tumor-associated antigen BCMA and the T cell activating receptor CD3. The drug, developed by Pfizer, is a new generation of targeted T-cell immune bridging therapy and is specifically designed to treat multiple myeloma, a highly heterogeneous hematological tumor.

From a structural point of view, enantuzumab is different from traditional single-target antibodies. It consists of two light chains and two heavy chains. It adopts an asymmetric construction method to have two functional binding arms in one molecule. The Fab structure at one end recognizes B cell maturation antigen (BCMA), which is expressed in multiple myeloid cells

The pharmaceutical ingredient is expressed in CHO cell line and prepared through efficient purification technology. It has a high degree of homogeneity and purity, minimizing immunogenicity issues. In addition, enatuzumab adopts a stable Fc structure modification to reduce the binding ability to Fcγ receptors, avoid non-specific immune activation, and at the same time extend its half-life in the body and improve bioavailability.

As an injection, eractuzumab is currently administered by subcutaneous injection. This route can effectively control the speed of immune activation, reduce the risk of cytokine release syndrome, and facilitate outpatient management. The molecular mass and three-dimensional structure of the drug have been verified through multiple rounds to ensure that it can stably exert its targeting effect in the body, and clinical trials have proven its stability and effectiveness in anti-myeloma treatment.

Overall, the pharmaceutical ingredients of enantuzumab represent the advanced level of antibody engineering technology. Its dual-targeting configuration not only improves treatment accuracy, but also provides a template for the future treatment of other hematological tumors.

Reference materials:https://www.drugs.com/mtm/elranatamab.html